Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2006Investigative Radiology

Assessment of Utilization and Pharmacovigilance Based on Spontaneous Adverse Event Reporting of Gadopentetate Dimeglumine as a Magnetic Resonance Contrast Agent After 45 Million Administrations and 15 Years of Clinical Use

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMichael V. KnoppThe Ohio State University Wexner Medical CenterTBThomas BalzerOncotherapeutics (United States)MEMarc EsserUniversitätsklinikum Aachen

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Knopp et al. (2006) studied this question.

synapsesocial.com/papers/6a942e8736938381f500ebabhttps://doi.org/10.1097/01.rli.0000209657.16115.42
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.1990 · 187 citations
  2. 2Gadolinium Chelates in Angiography and Interventional Radiology: A Useful Alternative to Iodinated Contrast Media for Angiography2002 · 126 citations
  3. 3Off-label use and reimbursement of contrast media in MR1999 · 26 citations
  4. 4Interference of Gadolinium-Containing Contrast-Enhancing Agents With Colorimetric Calcium Laboratory Testing2005 · 28 citations